EU IVDR makes performance evaluation continuous—not a study result

Performance evidence has three distinct components

The direct answer in Article 56 is that clinical evidence for an in vitro diagnostic device is not one laboratory number or one clinical study result. The regulation connects scientific validity, analytical performance, and clinical performance. Each answers a different question: whether the analyte or marker is associated with the condition or state, how the device detects or measures it, and how results correlate with the target clinical condition or process for the intended population and user.

A regulatory information or quality system should preserve the device and intended purpose, evidence category, protocol or source, population, specimen, method, comparator, acceptance criteria, result, limitation, version, reviewer, and conclusion. Flattening all evidence into a passed study flag removes the distinctions a qualified reviewer needs to assess sufficiency and applicability.

The report is a maintained conclusion—not an archive endpoint

The regulation requires a performance evaluation plan and a performance evaluation report within the technical documentation. The report brings the underlying evidence together and records the assessment supporting the device's clinical evidence. That makes the report a governed conclusion with traceable inputs, not a substitute for the source protocols, datasets, reports, searches, gaps, and review history behind it.

Buyers should ask a platform to reopen an approved evaluation after a changed intended purpose, new scientific publication, complaint pattern, analytical drift, software change, new specimen type, or post-market signal. The demonstration should preserve the former conclusion, identify affected evidence, route qualified review, and show why the current conclusion changed or remained supportable.

Post-market evidence closes the lifecycle loop

Article 56 and Annex XIII connect the evaluation to post-market performance follow-up and post-market surveillance. New information can therefore require reassessment after placing the device on the market. A workflow that closes permanently when the initial report is signed cannot represent the continuing evidence obligation described in the legal text.

Technology can support triggers, assignments, version control, linked evidence, review, approval, and reporting. It does not decide scientific validity, clinical benefit, conformity, or whether a particular data package is sufficient. Those conclusions remain with accountable regulatory, clinical, scientific, quality, statistical, and legal roles applying the current requirements and device facts.

Applicability and legal status stay explicit

Regulation (EU) 2017/746 applies within its stated scope and contains classification, transition, conformity-assessment, study, and evidence provisions whose operation depends on the device and facts. Teams should consult the current consolidated text, amendments, implementation measures, competent-authority material, and applicable standards rather than treating this article's summary as a universal checklist or effective-date determination.

This source establishes an EU legal evidence framework; it does not classify a device, authorize a study, approve a performance claim, certify software, or determine conformity. A system should make scope, source status, evidence category, lifecycle update, and accountable judgment visible without presenting a completed workflow as regulatory acceptance.

Enterprise buyer test

Translate this change into the exact population, record type, workflow stage, decision owner, effective date, and evidence that could be affected. Ask current or prospective providers to demonstrate the named workflow with representative data and an exception—not a polished feature tour. Record what official documentation establishes, what a provider states, what the team observes, and what remains unresolved.

A defensible review also identifies the dependency outside the product. Authority interpretation, policy configuration, data quality, integrations, human judgment, approval rights, release governance, training, and retained evidence may remain customer or service responsibilities. The evaluation should preserve those boundaries instead of treating a technology claim as the complete operating model.

What we will watch next

RegQuality Review will watch the named source and affected market records for later evidence that changes status, scope, availability, implementation timing, workflow consequence, or the limits of the initial report. A later announcement does not silently overwrite this dated account; the change ledger preserves the sequence.